CD274 and cervical carcinoma: The only ICI currently approved by the Food and Drug Administration (FDA) is Pembrolizumab: on 12 June 2018 approval was granted for patients with recurrent or metastatic PD-L1 positive cervical cancer with disease progression during or after chemotherapy.